StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)

Close on Nov 18, 2026Market cap $44.12MP/E –Yield –

Xilio Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xilio Therapeutics's total debt was $1.55M at Mar 31, 2023. For fiscal 2022 it was $3.17M, down 67.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2022Dec 31, 2022$3.17M-67.1%
FY2021Dec 31, 2021$9.63M+29.9%
FY2020Dec 31, 2020$7.41M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2023Mar 31, 2023$1.55M-80.7%
Q4 FY2022Dec 31, 2022$3.17M-67.1%
Q3 FY2022Sep 30, 2022$4.78M-50.1%
Q2 FY2022Jun 30, 2022$6.39M-13.7%
Q1 FY2022Mar 31, 2022$8.01M–
Q4 FY2021Dec 31, 2021$9.63M–
Q3 FY2021Sep 30, 2021$9.58M–
Q4 FY2020Dec 31, 2020$7.41M–

More Xilio Therapeutics figures

See a number that looks wrong?